z-logo
open-access-imgOpen Access
Evening Dosing of Antihypertensive Therapy to Reduce Cardiovascular Events: A Third Type of Evidence Based on a Systematic Review and Meta‐Analysis of Randomized Trials
Author(s) -
Roush George C.,
Fapohunda Jadesola,
Kostis John B.
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12354
Subject(s) - evening , dosing , medicine , meta analysis , morning , relative risk , blood pressure , randomized controlled trial , clinical trial , confidence interval , physics , astronomy
Nighttime blood pressure strongly predicts cardiovascular events ( CVE s). Further, a preliminary trial has shown decreased CVE s from evening vs morning dosing of antihypertensive therapy. Is there additional evidence for evening dosing? The authors systematically classified all hypertension trials as evening dosing trials ( EDT s) or usual dosing trials ( UDT s). Meta‐analyses provided standardized hazard ratios for CVE s for EDT s ( HR EDT s ) and UDT s ( HR UDT s ). HR EDT s / HR UDT s gave the relative risk ( RR ) from evening vs usual dosing. Among 175 trials, 5 EDT s were discovered. The RR for CVE s (95% confidence limits) from evening vs usual dosing was 0.63 (0.43–0.92; P =.016). After adjustment for drug class, the RR was 0.54 (0.34–0.85; P =.008). Unlike other EDT s, the Heart Outcomes Prevention Evaluation ( HOPE ) study administered its entire antihypertensive dose prior to sleep and gave the greatest risk reduction. This study provides a third type of evidence suggesting a beneficial effect from evening dosing of antihypertensive therapy. Head‐to‐head, multicenter trials are needed to test this strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here